Seqirus USA Inc
$16.7M 6,517 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Ipsen Biopharmaceuticals, Inc
Ipsen Biopharmaceuticals, Inc reported $16,775,240.38 across General Payments, Research, and Ownership to 20,198 physicians and teaching hospitals across 20,311 transactions.
- $16.8M Top 10% payer
- All-tracks total
- 20,311 Top 10% volume
- Transactions
- 20,198 Top 10% reach
- Recipients
- +$1.9M
- General Payments vs PY2023
Ipsen Biopharmaceuticals, Inc reported $16,775,240.38 across all CMS Open Payments tracks (General + Research + Ownership) to 20,198 physicians and teaching hospitals in Program Year 2024 - ranking #110 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $4,496,612.91, averaging $830.54 per recipient.
How Ipsen Biopharmaceuticals, Inc's $16.8M all-tracks total breaks down
Ipsen Biopharmaceuticals, Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
98/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer ipsen-biopharmaceuticals-inc Ipsen Biopharmaceuticals, Inc
$16.8M · #110/1,925 · 0.1% industry · PY2024
- TOT $16.8M
- RANK #110
- SHARE 0.1%
- TXN 20,311
- RCP 20,198
- CAT 7
- GEN $4.5M
- ΔGEN +$1.9M
- TOP1 2.5%
- PY 2024
Volume peers
Nearest volume peer: Seqirus USA Inc ($16.7M)
Ipsen Biopharmaceuticals, Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Ipsen Biopharmaceuticals, Inc's CMS-reported General Payments increased by $1.9M (+70.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: IPSEN BIOPHARMACEUTICALS, INCPY2023: IPSEN BIOPHARMACEUTICALS, INCPY2024: Ipsen Biopharmaceuticals, Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $2,633,962.24
- PY2024
- $4,496,612.91
What the Data Shows for Ipsen Biopharmaceuticals, Inc
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Ipsen Biopharmaceuticals, Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Compensation for Services Other Than Consulting" leads the 7-category general-payment breakdown below at $3.0M (66.0% of General Payments, 762 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads Ipsen Biopharmaceuticals, Inc's 7-category general-payment breakdown at $3.0M, 66.0% of the reported total.
Ipsen Biopharmaceuticals, Inc reports 7 general-payment categories - the top three are Compensation for Services Other Than Consulting (66.0%), Food and Beverage (12.8%), and Travel and Lodging (7.1%). The remaining 4 categories make up 14.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Ipsen Biopharmaceuticals, Inc divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $3.0M | 762 | 66.0% |
| Food and Beverage | $576.3K | 18,085 | 12.8% |
| Travel and Lodging | $318.5K | 809 | 7.1% |
| Space Rental or Facility Fees | $240.3K | 73 | 5.3% |
| Honoraria | $186.2K | 56 | 4.1% |
| Education | $114.8K | 383 | 2.6% |
| Consulting Fee | $92.7K | 30 | 2.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $501,284.01 (11.1%) of $4,496,612.91 in this company's General Payments records across 9,790 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Ipsen Biopharmaceuticals, Inc
The five named recipients with the highest reported General Payments from this company
- 1
Monica Verduzco-Gutierrez
$113,277.28 across 61 reported transactions
- 2
Rush University Medical Center
$103,457.00 across 2 reported transactions
- 3
Sonal Kumar
$96,598.80 across 50 reported transactions
- 4
Michael a Morse
$95,099.38 across 52 reported transactions
- 5
Naim Alkhouri
$92,851.55 across 43 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Ipsen Biopharmaceuticals, Inc ranks #110 of 1,925 by total payments (top 6% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,721 of 1,838 by HHI (bottom 6% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Seapearl East, Inc : $93.9K total payments, HHI 83
- Spinal Elements, Inc. : $50.6K total payments, HHI 83
- Tris Pharma Inc : $742.6K total payments, HHI 83
- Aquestive Therapeutics, Inc. : $5.5K total payments, HHI 81
- Notal Vision, Inc. : $13.1K total payments, HHI 81
- Atricure, Inc. : $4.9M total payments, HHI 80
- Ipsen Biopharmaceuticals, Inc (this company) : $4.5M total payments, HHI 79
- Pinnacle, Inc : $89.6K total payments, HHI 79
- Athena Bioscience, LLC : $2.0K total payments, HHI 78
- Bausch & Lomb Americas Inc. : $14.4M total payments, HHI 78
- Lightbody Medical Technologies Inc : $74.3K total payments, HHI 75
- Idorsia Pharmaceuticals US Inc : $1.2M total payments, HHI 75
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Ipsen Biopharmaceuticals, Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Ipsen Biopharmaceuticals, Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Ipsen Biopharmaceuticals, Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Janssen Pharmaceuticals, Inc
$16.8M 169,360 recipients
Compare payment profiles
Vanda Pharmaceuticals Inc.
$16.9M 38,897 recipients
Compare payment profiles
GastroGPO, LLC
$16.6M 8 recipients
Compare payment profiles
Alkermes, Inc.
$16.6M 83,613 recipients
Compare payment profiles
Endotronix, Inc.
$17.0M 179 recipients
Compare payment profiles
Put this to use
Ipsen Biopharmaceuticals, Inc ranks #110 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where Ipsen Biopharmaceuticals, Inc sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Ipsen Biopharmaceuticals, Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.